OMNIACTIVE’S OMNILEAN OBTAINS SELF-AFFIRMED GRAS NOTIFICATION

OmniActive’s OmniLean Obtains Self-Affirmed GRAS Notification

Morristown, N.J., December 13, 2016 – OmniActive’s OmniLean Salacia Extract has received self-affirmed GRAS (Generally Recognized as Safe) notification by an expert panel who evaluated the ingredient in accordance with stringent US Food and Drug Administration (FDA) safety criteria.

“OmniLean is a novel, differentiated ingredient with huge opportunity due to its formula flexibility and versatility in the metabolic health, weight management and satiety categories,” said Lynda M. Doyle, Sr. VP of Global Marketing, OmniActive. “OmniLean comes backed by OmniActive’s robust clinical program and GRAS self-affirmation which positions it as a unique, safe and effective ingredient.”

OmniLean, The Metabolic Synergizer, helps support metabolic health and was recently shown to reduce post prandial blood glucose and insulin in a human clinical trial in healthy individuals. Made from salacia, a genus of woody climbers and well known for its traditional use as a medicinal food supplement for various health benefits, OmniLean was developed as a fully traceable extract that supports multiple facets of weight management and metabolic health. OmniLean is a free-flowing powder that can be used in tablets, capsules, powders and bars for tremendous formulation flexibility.

About OmniActive Health Technologies

OmniActive Health Technologies (www.omniactives.com) offers a range of quality ingredients that are innovative and scientifically validated to address complex challenges for customers in the dietary supplement, food and beverage space using technology-driven, sustainable solutions with application support within a global regulatory framework. OmniActive’s core products include carotenoids, plant extracts and specialty functional ingredients. The company develops IP-protected, science-backed branded ingredients from natural sources using cutting edge technologies. OmniActive leverages international R&D strengths to deploy an array of state of the art manufacturing technologies in extraction, purification, isolation and delivery of nutritional actives. Clinical research geared towards demonstrating efficacy and claim substantiation is the cornerstone of OmniActive’s R&D activities. The company’s centers of excellence are located in North America and India, whereas its cGMP and HACCP system-compliant manufacturing operations are located at multiple FDA inspected sites in India. Whether looking for a new ingredient to add to a finished product, or technology to enhance an existing ingredient, OmniActive delivers unmatched innovation.

OmniLean is a trademark of OmniActive Health Technologies Ltd.
go back to PRESS RELEASES